See the DrugPatentWatch profile for cosentyx

The advised delay for live vaccine administration after Cosentyx (secukinumab) treatment is not explicitly stated in the drug's prescribing information or clinical trial data. However, it is generally recommended to avoid live vaccines during immunosuppressive therapy [1]. Cosentyx, a human monoclonal antibody, works by inhibiting interleukin-17A, which may increase the risk of infections [2].

Considering this, it is crucial to consult with the healthcare provider to determine the most appropriate vaccination schedule. The provider may consider the patient's overall health, immune status, and the specific vaccine's potential risks and benefits [1].

In summary, while there is no specific advised delay for live vaccine administration after Cosentyx treatment, it is generally recommended to avoid live vaccines during immunosuppressive therapy. Consult with a healthcare provider for personalized advice.

Sources:
[1] U.S. Food and Drug Administration. Cosentyx (secukinumab) injection, for subcutaneous use. Prescribing information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125557s000lbl.pdf>.
[2] DrugPatentWatch. Cosentyx (secukinumab). <https://www.drugpatentwatch.com/drugs/cosentyx>.